2,059 Shares in Integer Holdings Co. (NYSE:ITGR) Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp bought a new stake in Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,059 shares of the medical equipment provider’s stock, valued at approximately $204,000.

Other hedge funds have also bought and sold shares of the company. Cornercap Investment Counsel Inc. raised its position in Integer by 1.0% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider’s stock valued at $1,190,000 after purchasing an additional 121 shares in the last quarter. Strs Ohio raised its holdings in shares of Integer by 54.5% during the 4th quarter. Strs Ohio now owns 1,700 shares of the medical equipment provider’s stock valued at $168,000 after buying an additional 600 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in Integer in the 4th quarter worth approximately $1,655,000. Cerity Partners LLC purchased a new stake in Integer in the fourth quarter worth approximately $208,000. Finally, Wakefield Asset Management LLLP grew its position in Integer by 11.2% during the fourth quarter. Wakefield Asset Management LLLP now owns 9,796 shares of the medical equipment provider’s stock valued at $971,000 after acquiring an additional 990 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Stock Performance

Shares of NYSE:ITGR opened at $114.54 on Tuesday. The company has a current ratio of 3.32, a quick ratio of 2.01 and a debt-to-equity ratio of 0.76. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 39.63, a price-to-earnings-growth ratio of 1.53 and a beta of 1.10. Integer Holdings Co. has a 12 month low of $69.40 and a 12 month high of $123.99. The company has a 50-day moving average price of $113.41 and a 200-day moving average price of $100.35.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02. The business had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. Integer’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.87 EPS. As a group, equities analysts anticipate that Integer Holdings Co. will post 5.27 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ITGR shares. Benchmark restated a “buy” rating and issued a $130.00 price objective on shares of Integer in a report on Friday. Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. KeyCorp lifted their price objective on Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a report on Tuesday, April 9th. Finally, CL King assumed coverage on Integer in a report on Thursday, March 14th. They set a “buy” rating and a $137.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.